Tyrosine kinase inhibitors

Details Tyrosine kinase inhibitors Tyrosine kinase inhibitors

2008-03-25

2008-03-25

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S295000

Reexamination Certificate

active

10510609

ABSTRACT:
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

REFERENCES:
patent: 4332810 (1982-06-01), Belanger et al.
patent: WO 02/24692 (2002-03-01), None
patent: WO 03 086315 (2003-10-01), None
patent: WO 03 086395 (2003-10-01), None
Caplus, english abstract DN 113:131976, Iddon Brian et al , 1990 Pertin transcaction !, “Synthesis and recations of 2,3,5, 6-tetrahydro-2,5-ethano-3-benzazocin-4(1H)-one.”
Belanger, et al., Can. J. Chem., vol. 61, pp. 2177-2182, 1983.
Iddon, et al., J. Chem. Soc. Perkin Trans., vol. 4, pp. 1083-1090, 1990.
Workman, et al., Seminars in Cancer Biology, vol. 3, pp. 369-381, 1992.
Belanger, et al., J. Org. Chem., vol. 47, pp. 4329-4334, 1982.
Paradisi, et al., Tetrahedron: Asymmetry, vol. 11, pp. 4617-4622, 2000.

Affiliated with

Also associated with

Rating

Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3917447